# Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)

> **NCT00105469** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 743 (actual)

## Conditions studied

- Bacterial Conjunctivitis

## Interventions

- **DRUG:** AzaSite
- **DRUG:** Tobramycin

## Key facts

- **NCT ID:** NCT00105469
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 743 (ACTUAL)
- **Last updated:** 2013-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00105469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00105469, "Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00105469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*